AI Article Synopsis

  • Anti-amyloid drugs like lecanemab used for early Alzheimer's disease can cause adverse events (AEs), including specific brain imaging abnormalities and infusion reactions.
  • A meta-analysis was conducted to assess the predictive value of these adverse events, revealing that ARIA-E has a high positive predictive value (PPV) of 0.915, while ARIA hemorrhage has a low PPV of 0.630.
  • The findings indicate that the impact of AEs, especially ARIA-E, can influence the results of clinical trials and emphasize the need to reduce potential biases stemming from these events.

Article Abstract

Anti-amyloid drugs for early Alzheimer's disease, including lecanemab, are associated with adverse events (AEs), such as amyloid-related imaging abnormalities (ARIA)-edema/effusion (E), ARIA-hemorrhage, and infusion-related reactions, which can indicate allocated arms in clinical trials. Herein, we evaluated the predictive value of AEs using a meta-analysis to estimate their incidence and simulated positive predictive value (PPV). The PPV for ARIA-E was high (0.915), but that for ARIA hemorrhage was low (0.630). Infusion-related reactions had a high PPV of 0.910, but with a wide confidence interval. Our results suggest the need to ameliorate the unblinding effects of AEs, particularly ARIA-E in trials.

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-240623DOI Listing

Publication Analysis

Top Keywords

adverse events
8
allocated arms
8
infusion-related reactions
8
events unblinding
4
unblinding allocated
4
arms anti-amyloid
4
anti-amyloid therapy
4
therapy trials
4
trials meta-analysis
4
meta-analysis predictive
4

Similar Publications

Background: Type 1 diabetes is a serious, chronic disorder with an increasing incidence among children and adolescents. Glycemic control in individuals with type 1 diabetes is better managed through a basal-bolus regimen with either regular human or rapid-acting insulin analogues administered as a bolus at mealtimes. Rapid-acting insulin analogues have been hypothesized to cause optimal glycemic control and less risk of hypoglycemic episodes compared to regular human insulins.

View Article and Find Full Text PDF

Comparison of hypothermic and normothermic targeted temperature management in out-of-hospital cardiac arrest patients with acute coronary syndrome: a nationwide retrospective study.

Crit Care

January 2025

Division of Environmental Medicine and Population Services, Department of Social and Environmental Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.

Background: Targeted temperature management (TTM) is considered a beneficial treatment for improving outcomes in patients with OHCA due to acute coronary syndrome (ACS). The comparative benefits of hypothermic TTM (32-34°C) versus normothermic TTM (35-36°C) are unclear. This study compares these TTM strategies in improving neurological outcomes and survival rates in OHCA patients with ACS.

View Article and Find Full Text PDF

Background: Neoadjuvant chemotherapy (NACT) is the standard-of-care treatment for patients with locally advanced breast cancer (LABC), providing crucial benefits in tumor downstaging. Clinical parameters, such as molecular subtypes, influence the therapeutic impact of NACT. Moreover, severe adverse events delay the treatment process and reduce the effectiveness of therapy.

View Article and Find Full Text PDF

Background: Compassion Competence and the ability to strive to understand the suffering of patients in psychiatric ward is essential for nurses to establish effective therapeutic communication in the process of their recovery. Patient Safety Competency is of great importance for nurses to prevent adverse events and minimize errors. This study aimed to investigate the relationship between Compassion Competence and Patient Safety Competency in nurses working in psychiatric wards of Shiraz University of Medical Sciences affiliated hospitals in 2024.

View Article and Find Full Text PDF

Efficacy and safety of ondansetron orally soluble pellicle for preventing moderate- to high-emetic risk chemotherapy-induced nausea and vomiting.

BMC Cancer

January 2025

Department of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 116 South Zuodaoquan Road, Wuhan, 430079, China.

Objective: Ondansetron orally soluble pellicle can serve as an alternative option for preventing nausea and vomiting in patients who receive chemotherapy. However, there is a lack of clinical evidence regarding ondansetron. This study aimed to explore the efficacy and safety of ondansetron in patients with malignant tumours who received chemotherapy drugs with a moderate-to-high emetic risk.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!